S&P 500   4,360.91 (-1.12%)
DOW   34,321.43 (-0.13%)
QQQ   347.74 (-1.57%)
AAPL   161.38 (-0.15%)
MSFT   291.90 (-1.51%)
FB   303.71 (-1.62%)
GOOGL   2,566.74 (-1.89%)
AMZN   2,812.08 (-2.73%)
TSLA   934.49 (+0.48%)
NVDA   226.02 (-3.29%)
BABA   120.33 (-0.03%)
NIO   24.08 (-3.18%)
AMD   112.34 (-3.60%)
CGC   7.42 (+0.27%)
MU   81.30 (-1.99%)
GE   91.42 (-5.67%)
T   26.48 (+0.53%)
F   20.14 (-1.23%)
DIS   137.09 (-0.27%)
AMC   16.21 (-2.58%)
PFE   52.46 (+1.79%)
ACB   4.24 (-1.85%)
BA   204.74 (+0.26%)
S&P 500   4,360.91 (-1.12%)
DOW   34,321.43 (-0.13%)
QQQ   347.74 (-1.57%)
AAPL   161.38 (-0.15%)
MSFT   291.90 (-1.51%)
FB   303.71 (-1.62%)
GOOGL   2,566.74 (-1.89%)
AMZN   2,812.08 (-2.73%)
TSLA   934.49 (+0.48%)
NVDA   226.02 (-3.29%)
BABA   120.33 (-0.03%)
NIO   24.08 (-3.18%)
AMD   112.34 (-3.60%)
CGC   7.42 (+0.27%)
MU   81.30 (-1.99%)
GE   91.42 (-5.67%)
T   26.48 (+0.53%)
F   20.14 (-1.23%)
DIS   137.09 (-0.27%)
AMC   16.21 (-2.58%)
PFE   52.46 (+1.79%)
ACB   4.24 (-1.85%)
BA   204.74 (+0.26%)
S&P 500   4,360.91 (-1.12%)
DOW   34,321.43 (-0.13%)
QQQ   347.74 (-1.57%)
AAPL   161.38 (-0.15%)
MSFT   291.90 (-1.51%)
FB   303.71 (-1.62%)
GOOGL   2,566.74 (-1.89%)
AMZN   2,812.08 (-2.73%)
TSLA   934.49 (+0.48%)
NVDA   226.02 (-3.29%)
BABA   120.33 (-0.03%)
NIO   24.08 (-3.18%)
AMD   112.34 (-3.60%)
CGC   7.42 (+0.27%)
MU   81.30 (-1.99%)
GE   91.42 (-5.67%)
T   26.48 (+0.53%)
F   20.14 (-1.23%)
DIS   137.09 (-0.27%)
AMC   16.21 (-2.58%)
PFE   52.46 (+1.79%)
ACB   4.24 (-1.85%)
BA   204.74 (+0.26%)
S&P 500   4,360.91 (-1.12%)
DOW   34,321.43 (-0.13%)
QQQ   347.74 (-1.57%)
AAPL   161.38 (-0.15%)
MSFT   291.90 (-1.51%)
FB   303.71 (-1.62%)
GOOGL   2,566.74 (-1.89%)
AMZN   2,812.08 (-2.73%)
TSLA   934.49 (+0.48%)
NVDA   226.02 (-3.29%)
BABA   120.33 (-0.03%)
NIO   24.08 (-3.18%)
AMD   112.34 (-3.60%)
CGC   7.42 (+0.27%)
MU   81.30 (-1.99%)
GE   91.42 (-5.67%)
T   26.48 (+0.53%)
F   20.14 (-1.23%)
DIS   137.09 (-0.27%)
AMC   16.21 (-2.58%)
PFE   52.46 (+1.79%)
ACB   4.24 (-1.85%)
BA   204.74 (+0.26%)
NASDAQ:PTE

PolarityTE Stock Forecast, Price & News

$0.53
+0.01 (+2.25%)
(As of 01/25/2022 03:32 PM ET)
Add
Compare
Today's Range
$0.52
$0.54
50-Day Range
$0.39
$0.73
52-Week Range
$0.38
$1.99
Volume
1,691 shs
Average Volume
2.91 million shs
Market Capitalization
$43.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.02
30 days | 90 days | 365 days | Advanced Chart
Receive PTE News and Ratings via Email

Sign-up to receive the latest news and ratings for PolarityTE and its competitors with MarketBeat's FREE daily newsletter.


PolarityTE logo

About PolarityTE

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Headlines

PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study
January 19, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTE
Employees
83
Year Founded
N/A

Sales & Book Value

Annual Sales
$10.13 million
Book Value
$0.45 per share

Profitability

Net Income
$-42.85 million
Net Margins
-265.02%
Pretax Margin
-265.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
79,065,000
Market Cap
$43.50 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/25/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.93 out of 5 stars

Medical Sector

1293rd out of 1,416 stocks

Biological Products, Except Diagnostic Industry

194th out of 206 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












PolarityTE (NASDAQ:PTE) Frequently Asked Questions

How has PolarityTE's stock price been impacted by COVID-19 (Coronavirus)?

PolarityTE's stock was trading at $1.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PTE shares have decreased by 50.4% and is now trading at $0.5309.
View which stocks have been most impacted by COVID-19
.

Are investors shorting PolarityTE?

PolarityTE saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,360,000 shares, an increase of 55.3% from the December 15th total of 1,520,000 shares. Based on an average daily trading volume, of 941,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 3.5% of the shares of the stock are short sold.
View PolarityTE's Short Interest
.

When is PolarityTE's next earnings date?

PolarityTE is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for PolarityTE
.

How were PolarityTE's earnings last quarter?

PolarityTE, Inc. (NASDAQ:PTE) released its earnings results on Wednesday, November, 10th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. The firm earned $1.12 million during the quarter, compared to analyst estimates of $0.97 million. PolarityTE had a negative trailing twelve-month return on equity of 102.66% and a negative net margin of 265.02%. During the same quarter last year, the business earned ($0.18) EPS.
View PolarityTE's earnings history
.

Who are PolarityTE's key executives?

PolarityTE's management team includes the following people:
  • Richard Hague, President & Chief Executive Officer (LinkedIn Profile)
  • Jacob Patterson, Chief Financial Officer
  • Stephen Milner, Chief Clinical Officer
  • Ryan Mathis, Chief Medical Officer
  • Nikolai Sopko, CSO, VP-Research & Development

What other stocks do shareholders of PolarityTE own?

What is PolarityTE's stock symbol?

PolarityTE trades on the NASDAQ under the ticker symbol "PTE."

How do I buy shares of PolarityTE?

Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PolarityTE's stock price today?

One share of PTE stock can currently be purchased for approximately $0.53.

How much money does PolarityTE make?

PolarityTE has a market capitalization of $43.50 million and generates $10.13 million in revenue each year. The company earns $-42.85 million in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does PolarityTE have?

PolarityTE employs 83 workers across the globe.

What is PolarityTE's official website?

The official website for PolarityTE is www.polarityte.com.

Where are PolarityTE's headquarters?

How can I contact PolarityTE?

PolarityTE's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at (800) 560-3983, via email at [email protected], or via fax at 302-636-5454.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.